MARIANNE, NCT01120184 / 2009-017905-13: A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer |
|
|
| Completed | 3 | 1095 | Europe, Canada, Japan, US, RoW | docetaxel, paclitaxel, pertuzumab, pertuzumab-placebo, trastuzumab [Herceptin], trastuzumab emtansine | Hoffmann-La Roche, Genentech, Inc. | Breast Cancer | 09/14 | 09/16 | | |
GeparOcto, NCT02125344 / 2014-000619-14: A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer |
|
|
| Completed | 3 | 961 | Europe | non-pegylated liposomal doxorubicin, Myocet, Carboplatin, Carbomedac, Paclitaxel, var., Epirubicin, Farmorubicin, Cyclophosphamide, Endoxan, Pertuzumab, Perjeta, Trastuzumab, Herceptin, Ferric carboxymaltose, Ferinject | German Breast Group, Amgen, Roche Pharma AG, Teva Pharmaceuticals USA, Vifor Pharma | Tubular Breast Cancer Stage II, Tubular Breast Cancer Stage III, Mucinous Breast Cancer Stage II, Breast Cancer Female NOS, Invasive Ductal Breast Cancer, HER2 Positive Breast Cancer, Inflammatory Breast Cancer | 11/16 | 01/17 | | |
SAPPHIRE, NCT02019277: A Study of Pertuzumab and Trastuzumab Subcutaneous (SC) Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer |
|
|
| Completed | 3 | 50 | RoW | Docetaxel, Nab-paclitaxel, Paclitaxel, Pertuzumab, Perjeta, Trastuzumab, Herceptin | Hoffmann-La Roche | Breast Cancer | 11/16 | 11/16 | | |
